-+ 0.00%
-+ 0.00%
-+ 0.00%

Vera Therapeutics pulls forward ORIGIN phase 3 eGFR analysis of atacicept in IgA nephropathy to Q3 2026

PUBT·06/02/2026 11:03:58
Listen to the news
Vera Therapeutics pulls forward ORIGIN phase 3 eGFR analysis of atacicept in IgA nephropathy to Q3 2026
  • Vera Therapeutics aligned with the FDA to pull forward a key Phase 3 kidney-function analysis for atacicept in IgA nephropathy to Q3 2026.
  • Results will be presented in the future; the earlier readout is intended to support a path to full approval if outcomes are positive.
  • The BLA for accelerated approval has a PDUFA date of July 7, 2026.
  • Prior ORIGIN Phase 3 interim results were already presented, showing the trial met its primary goal with a clinically meaningful improvement versus placebo.
  • Pending the Q3 2026 readout, a supplemental BLA is planned for Q4 2026, targeting potential full approval in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020700PRIMZONEFULLFEED9730064) on June 02, 2026, and is solely responsible for the information contained therein.